Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Nath Bio-Genes (India) Ltd

About the Company - Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd. is a Public Limited Listed company incorporated on 14/07/1993 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L01110MH1993PLC072842 and registration number is 072842. Currently Company is involved in the business activities of Growing of non-perennial crops. Company’s Total Operating Revenue is Rs. 278.36 Cr. and Equity Capital is Rs. 19.00 Cr. for the Year ended 31/03/2022.
Seeds/Tissue Culture/Bio TechnologyNath House, Nath Road, Aurangabad Maharashtra
NamePosition Held
Mr. Satish KagliwalManaging Director
Mr. Madhukar DeshpandeDirector
Ms. Ashu JainDirector
Mrs. Jeevanlata KagliwalDirector
Mr. Vadla NagabhushanamDirector
Mrs. Sweta KagliwalDirector
Mr. Hitesh PurohitDirector

Nath Bio-Genes (India) Ltd. Share Price Update

Share PriceValue
Previous Day₹204.05

Basic Stock Data of Nath Bio-Genes (India) Ltd

Market Cap 402 Cr.
Current Price 211
High / Low245/136
Stock P/E10.6
Book Value 318
Dividend Yield0.94 %
ROCE7.08 %
ROE6.31 %
Face Value 10.0

Data Source:

Competitors of Nath Bio-Genes (India) Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Shreeoswal Seeds & Chemicals Ltd 373 Cr. 40.870.9/39.2 5.140.00 %14.0 %13.8 % 2.00
Continental Seeds and Chemicals Ltd 23.9 Cr. 23.934.4/12.2 12.40.00 %3.30 %2.69 % 10.0
Industry Average198.45 Cr32.350.008.770.00%8.65%8.25%6.00

Nath Bio-Genes (India) Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit5.857.3111.0348.534.806.29-21.2634.484.755.624.0837.025.52
OPM %24.67%19.78%20.09%22.56%31.50%28.67%-78.13%16.47%21.86%22.21%9.08%15.73%24.46%
Other Income0.
Profit before tax3.174.547.4945.191.342.91-112.8330.931.532.051.8233.622.38
Tax %4.73%6.39%4.67%0.62%8.21%3.44%-3.07%0.55%3.92%34.15%12.64%0.65%14.71%
Net Profit3.014.257.1444.911.232.81-116.2930.761.471.351.5933.402.03
EPS in Rs1.582.243.7623.630.651.48-61.1916.190.770.710.8417.581.07

Nath Bio-Genes (India) Ltd Quarterly Chart

Nath Bio-Genes (India) Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit15203435252940435567374952
OPM %15%18%25%24%19%20%24%21%22%25%16%21%16%
Other Income1111101222-8713
Profit before tax9122626151730394957-633642
Tax %-1%4%5%4%6%3%2%1%-4%2%-6%3%
Net Profit9122425141629385056-673541
EPS in Rs5.757.3415.1815.878.8510.1715.4820.2226.5629.29-35.4318.5121.34
Dividend Payout %0%0%0%0%0%0%0%0%0%7%-6%11%

Nath Bio-Genes (India) Ltd Profit & Loss Yearly Chart

Nath Bio-Genes (India) Ltd Growth

Compounded Sales Growth
10 Years:8%
5 Years:6%
3 Years:-2%
Compounded Profit Growth
10 Years:12%
5 Years:4%
3 Years:-11%
Stock Price CAGR
10 Years:16%
5 Years:-8%
3 Years:-7%
1 Year:45%
Return on Equity
10 Years:9%
5 Years:7%
3 Years:7%
Last Year:6%

Nath Bio-Genes (India) Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital16161616161619191919191919
Other Liabilities636785978778698010275105114130
Total Liabilities120143190226267455571646730790740793847
Fixed Assets2118171330207211232246247245244243
Other Assets99120168208231243355409479538490544598
Total Assets120143190226267455571646730790740793847

Nath Bio-Genes (India) Ltd Reserves and Borrowings Chart

Nath Bio-Genes (India) Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 156-143-47-23911738
Cash from Investing Activity -16-2-17-4-4-20-14-10-20-3
Cash from Financing Activity 1-43059020616-22-2
Net Cash Flow-0-1-0539-2317-2534

Nath Bio-Genes (India) Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days477095114130133175191159147136152
Inventory Days5873,8404,7434,388
Days Payable1461,3091,406586
Cash Conversion Cycle48770951141302,6653,5121911591471363,954
Working Capital Days109167179242383398515544519585573579
ROCE %20%24%33%26%14%10%9%8%9%10%5%7%

Nath Bio-Genes (India) Ltd Financial Efficiency Indicators Chart

Nath Bio-Genes (India) Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders27,44425,63031,67333,27233,92635,61035,48435,47034,74933,96033,50234,365

Nath Bio-Genes (India) Ltd Shareholding Pattern Chart

No. of Nath Bio-Genes (India) Ltd Shareholders

Nath Bio-Genes (India) Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Aditya Birla Sun Life Pure Value Fund8285950.3216.53

Nath Bio-Genes (India) Ltd ROCE Trend

Nath Bio-Genes (India) Ltd EPS Trend

Nath Bio-Genes (India) Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 13Mar 12
Basic EPS (Rs.)18.43-35.557.345.75
Diluted EPS (Rs.)18.43-35.557.345.75
Cash EPS (Rs.)20.01-33.8410.168.69
Book Value[Excl.RevalReserv]/Share (Rs.)301.60285.1635.9128.57
Book Value[Incl.RevalReserv]/Share (Rs.)301.60285.1635.9128.57
Revenue From Operations / Share (Rs.)158.58146.4786.0477.43
PBDIT / Share (Rs.)25.9420.5412.8010.61
PBIT / Share (Rs.)24.3618.929.987.67
PBT / Share (Rs.)19.03-33.387.686.54
Net Profit / Share (Rs.)18.42-35.467.345.75
NP After MI And SOA / Share (Rs.)18.42-35.467.345.75
PBDIT Margin (%)16.3514.0214.8713.70
PBIT Margin (%)15.3512.9111.599.90
PBT Margin (%)12.00-22.788.928.45
Net Profit Margin (%)11.61-24.208.527.42
NP After MI And SOA Margin (%)11.61-24.208.527.42
Return on Networth / Equity (%)6.10-12.4320.4320.12
Return on Capital Employeed (%)8.036.5926.5425.62
Return On Assets (%)4.41-9.117.427.67
Long Term Debt / Equity (X)
Total Debt / Equity (X)
Asset Turnover Ratio (%)0.390.001.050.00
Current Ratio (X)2.412.411.221.34
Quick Ratio (X)1.451.270.430.42
Dividend Payout Ratio (NP) (%)10.85-5.640.000.00
Dividend Payout Ratio (CP) (%)9.99-5.910.000.00
Earning Retention Ratio (%)89.15105.640.000.00
Cash Earning Retention Ratio (%)90.01105.910.000.00
Interest Coverage Ratio (X)4.873.685.589.40
Interest Coverage Ratio (Post Tax) (X)4.463.024.206.87
Enterprise Value (Cr.)336.48494.220.000.00
EV / Net Operating Revenue (X)1.121.780.000.00
EV / EBITDA (X)6.8312.660.000.00
MarketCap / Net Operating Revenue (X)0.891.460.000.00
Retention Ratios (%)89.14105.640.000.00
Price / BV (X)0.460.740.000.00
Price / Net Operating Revenue (X)0.891.460.000.00

Nath Bio-Genes (India) Ltd Profitability Ratios (%)

Nath Bio-Genes (India) Ltd Liquidity Ratios

Nath Bio-Genes (India) Ltd Liquidity Ratios (%)

Nath Bio-Genes (India) Ltd Interest Coverage Ratios (%)

Nath Bio-Genes (India) Ltd Valuation Ratios

Fair Value of Nath Bio-Genes (India) Ltd Stock

Fair Value: ₹214.70

The stock is undervalued by 1.75% compared to the current price ₹211

*Investments are subject to market risks

Strength and Weakness of Nath Bio-Genes (India) Ltd Stock

  1. The company has higher reserves (335.00 cr) compared to borrowings (60.08 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (188.23 cr) and profit (22.69 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 15.23 and average Dividend Yield of 12.44%.
  2. The stock has a low average ROCE of 14.58%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 399.42, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 128.08, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nath Bio-Genes (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE